Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Xanomeline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 13/20 | 1.00 |
| ▸ | CHRM4 known ✓ | P08173 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6913473 | 1.00 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL6907880 | 1.00 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Xanomeline SCHEMBL31112303 | 0.99 | CHRM1 (0.98) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Xanomeline SCHEMBL18049053 | 0.99 | CHRM1 (0.98) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL6913174 | 0.99 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL6906658 | 0.95 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL4035543 | 0.95 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Oxalic Acid SCHEMBL7621656 | 0.93 | CHRM1 (0.87) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Oxalic Acid SCHEMBL7616095 | 0.93 | CHRM1 (0.87) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Xanomeline SCHEMBL38662546 | 0.93 | CHRM1 (0.87) | CHRM1CHRM4CHRM2CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3661 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146048-A1 | NOVEL BISINDOLYLMALEIMIDE KINASE INHIBITORS | 4M THERAPEUTICS INC. (US) | 2026-05-28 | — | — | US | claimed |
| WO-2026106908-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | NEUHYLL THERAPEUTICS INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-3646870-B1 | COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | PureTech Health LLC (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122056831-A | Nasal solution of taking-up NOMELIN, preparation method and application thereof | 纳索菲德(上海)制药技术有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260130896-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739312-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS Therapeutics LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4729060-A2 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARNIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260102350-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | KARUNA THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12558317-B2 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | Karuna Therapeutics, Inc. (US) | 2026-02-24 | — | — | US | claimed |
| WO-1996014066-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1996-05-17 | — | — | WO | claimed |
| EP-0709095-A2 | Method for treating anxiety using a tetrahydropyridine or azabicyclic oxadiazole or thiadiazole compound | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | claimed |
| EP-0703915-A1 | HETEROCYCLIC CHEMISTRY | NOVO NORDISK A/S (DK) | 1996-04-03 | — | — | EP | claimed |
| US-5488056-A | 1,2,5-THIADIAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-01-30 | — | — | US | claimed |
| EP-0384288-B1 | Piperidine compounds and their preparation and use | NOVO NORDISK AS (DK) | 1995-05-24 | — | — | EP | claimed |
| WO-1995005174-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1995-02-23 | — | — | WO | claimed |
| WO-1994029303-A1 | HETEROCYCLIC CHEMISTRY | NOVO NORDISK A/S (DK) | 1994-12-22 | — | — | WO | claimed |
| WO-1994009787-A1 | SYNERGISTIC COMBINATION FOR THE THERAPY OF DEGENERATIVE AGEING DISEASES CONTAINING AN ADENOSINE ANTAGONIST AND A CHOLINOMIMETIC | BOEHRINGER INGELHEIM KG (DE) | 1994-05-11 | — | — | WO | claimed |
| US-5043345-A | Cognition activators; alzheimer's disease | NOVO NORDISK A/S (DK) | 1991-08-27 | — | — | US | claimed |
| EP-0384288-A2 | Piperidine compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1990-08-29 | — | — | EP | claimed |